Statement Of Cash Flows [Abstract]

Pharming Group N.V. - Filing #1859781

Concept 2021-01-01 to
2021-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
As at
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
As at
2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
USD
USD
USD
USD
USD
USD
15,996,000 USD
15,996,000 USD
37,746,000 USD
37,746,000 USD
USD
USD
USD
USD
USD
USD
Adjustments to reconcile profit (loss) [abstract]
Adjustments for finance costs
6,196,000 USD
33,308,000 USD
Adjustments for decrease (increase) in inventories
6,153,000 USD
4,934,000 USD
Adjustments for share-based payments
9,056,000 USD
6,537,000 USD
Adjustments for fair value losses (gains)
114,000 USD
69,000 USD
Adjustments for undistributed profits of associates
694,000 USD
362,000 USD
Other adjustments for non-cash items
524,000 USD
1,624,000 USD
Interest received, classified as operating activities
53,000 USD
715,000 USD
Income taxes paid (refund), classified as operating activities
USD
2,658,000 USD
Cash flows from (used in) operating activities
37,842,000 USD
83,626,000 USD
Cash flows from (used in) investing activities [abstract]
Other cash payments to acquire equity or debt instruments of other entities, classified as investing activities
4,589,000 USD
USD
Purchase of property, plant and equipment, classified as investing activities
10,739,000 USD
4,657,000 USD
Purchase of intangible assets, classified as investing activities
3,447,000 USD
9,060,000 USD
Cash flows from (used in) investing activities
21,305,000 USD
15,629,000 USD
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing other equity instruments
4,718,000 USD
2,791,000 USD
Repayments of borrowings, classified as financing activities
USD
57,231,000 USD
Payments of lease liabilities, classified as financing activities
3,217,000 USD
2,186,000 USD
Interest paid, classified as financing activities
4,448,000 USD
2,142,000 USD
Cash flows from (used in) financing activities
27,947,000 USD
60,686,000 USD
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
11,410,000 USD
128,683,000 USD
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
1,825,000 USD
2,128,000 USD
Cash and cash equivalents
191,924,000 USD
205,159,000 USD
74,348,000 USD

Talk to a Data Expert

Have a question? We'll get back to you promptly.